CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 71 enrolled
Drug / intervention
Dichlorphenamide (double-blind) +2 moredrug
Likely dose
Dichlorphenamide (double-blind) 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00494507
NCT00494507Phase 3Completed
CompareCT.gov

Dichlorphenamide vs. Placebo for Periodic Paralysis

University of Rochester·interventional·Posted Jun 29, 2007·Updated Jun 14, 2017

In Brief

A Phase 3 clinical trial evaluating Dichlorphenamide (double-blind), Placebo (double-blind), and 1 other intervention for Hyperkalemic Periodic Paralysis and Hypokalemic Periodic Paralysis. Completed, enrolled 71 participants across 12 sites in 3 countries.

Detailed Summary

The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperkalemic Periodic Paralysis, Hypokalemic Periodic Paralysis
CountriesItaly, United Kingdom, United States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 29, 2007
Enrollment StartJun 1, 2007
Primary CompletionApr 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 19.0 years ago

Interventions

Dichlorphenamide (double-blind)drug

50mg tablet; maximum dosage 400mg/day

Placebo (double-blind)drug

Inactive substance manufactured to look like Dichlorphenamide 50mg tablet

Dichlorphenamide (open-label)drug

50mg tablet; maximum dosage 400mg/day